- ISIN
- JE00BYSS4X48
- CUSIP
- 852387208
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- IPO Date
- Oct 2, 2015
Highlights
- Market Cap
- $1.55B
- Enterprise Value
- $1.73B
- EPS (TTM)
- -$1.54
- Total Revenue (TTM)
- $674.41M
- Gross Profit (TTM)
- $507.13M
- EBITDA (TTM)
- -$164.04M
- Year Range
- $9.82 - $18.92
- Target Price
- $33.50
- ROE (TTM)
- -52.32%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NVCR Performance Chart
NovoCure Limited (NVCR) is up 5.3% since the beginning of the year. At $14 per share, NVCR is trading 28.1% below its 52-week high of $19. Investors who bought $1,000 worth of NVCR shares 5 years ago would now be looking at an investment worth $60.
Loading charts...
Returns By Period
NovoCure Limited (NVCR) has returned 5.26% so far this year and -18.45% over the past 12 months. Over the last ten years, NVCR has returned 2.52% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
NovoCure Limited
- 1D
- -4.69%
- 1M
- -24.22%
- YTD
- 5.26%
- 6M
- 1.26%
- 1Y
- -18.45%
- 3Y*
- -31.19%
- 5Y*
- -42.97%
- 10Y*
- 2.52%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
NVCR Monthly Returns History
Based on dividend-adjusted daily data since Oct 2, 2015, NVCR's average daily return is +0.09%, while the average monthly return is +1.71%. At this rate, an investment would double in approximately 3.4 years.
Historically, 49% of months were positive and 51% were negative. The best month was May 2024 with a return of +79.8%, while the worst month was Jan 2016 at -44.2%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.
On a daily basis, NVCR closed higher 49% of trading days. The best single day was Jan 5, 2023 with a return of +68.5%, while the worst single day was Jun 6, 2023 at -43.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.10% | 10.24% | -20.26% | 39.54% | 12.03% | -20.13% | 5.26% | ||||||
| 2025 | -17.72% | -22.23% | -6.55% | 1.80% | 5.35% | -6.86% | -35.00% | 6.57% | 4.79% | -0.85% | -0.00% | 0.94% | -56.61% |
| 2024 | -6.76% | 9.99% | 2.09% | -21.69% | 79.82% | -22.17% | 32.92% | -14.62% | -19.60% | -2.88% | 32.02% | 48.70% | 99.60% |
| 2023 | 24.31% | -15.58% | -21.87% | 9.58% | 8.97% | -42.21% | -21.35% | -32.41% | -26.79% | -17.65% | -7.74% | 21.68% | -79.65% |
| 2022 | -8.56% | 19.24% | 1.21% | -7.57% | 4.96% | -13.54% | -2.17% | 20.80% | -7.49% | -7.00% | 8.75% | -4.54% | -2.30% |
| 2021 | -6.98% | -7.37% | -11.35% | 54.41% | -0.05% | 8.74% | -30.57% | -12.86% | -13.44% | -11.71% | -8.71% | -19.82% | -56.61% |
Benchmark Metrics
NovoCure Limited has an annualized alpha of 4.93%, beta of 1.25, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since October 02, 2015.
- This stock participated in 154.86% of S&P 500 Index downside but only 83.37% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 4.93%
- Beta
- 1.25
- R²
- 0.09
- Upside Capture
- 83.37%
- Downside Capture
- 154.86%
Return for Risk
Risk / Return Rank
NVCR ranks 32 for risk / return — below 32% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for NovoCure Limited (NVCR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVCR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.27 | ||
| Sortino ratioReturn per unit of downside risk | -2.59 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.37 | -0.35 |
| Calmar ratioReturn relative to maximum drawdown | -0.41 | 2.78 | -3.19 |
| Martin ratioReturn relative to average drawdown | -0.63 | 12.44 | -13.07 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NovoCure Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NovoCure Limited was 95.55%, occurring on Feb 9, 2026. The portfolio has not yet recovered.
The current NovoCure Limited drawdown is 93.97%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -95.55%Feb 2026 | 4y 7mo | — | 5y 6hJun 2021 - now |
2016 bear market2016 | -78.83%Nov 2016 | 10mo 21d | 1y 6mo | 2y 4moDec 2015 - May 2018 |
Rate-hike selloffLate 2018 | -45.43%Nov 2018 | 1mo 17d | 2mo 27d | 4mo 14dOct 2018 - Feb 2019 |
COVID crash2020 | -41.67%Mar 2020 | 7mo 4d | 5mo 26d | 1y 25dAug 2019 - Sep 2020 |
2021 bear market2021 | -34.74%Mar 2021 | 1mo 5d | 15d | 1mo 20dFeb 2021 - Apr 2021 |
Drawdown Indicators
| NVCR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.55% | -56.78% | -38.77% |
Max Drawdown (1Y)Largest decline over 1 year | -45.67% | -9.10% | -36.57% |
Max Drawdown (3Y)Largest decline over 3 years | -76.32% | -18.90% | -57.42% |
Max Drawdown (5Y)Largest decline over 5 years | -95.52% | -25.43% | -70.09% |
Max Drawdown (10Y)Largest decline over 10 years | -95.55% | -33.92% | -61.63% |
Current DrawdownCurrent decline from peak | -93.97% | -1.80% | -92.17% |
Average DrawdownAverage peak-to-trough decline | -52.31% | -10.71% | -41.60% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 29.35% | 2.03% | +27.32% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NovoCure Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NovoCure Limited is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NVCR relative to other companies in the Medical Instruments & Supplies industry. Currently, NVCR has a P/S ratio of 2.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NVCR in comparison with other companies in the Medical Instruments & Supplies industry. Currently, NVCR has a P/B value of 4.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NVCR
Add NovoCure Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NVCR